Tesamorelin For Visceral Fat When Your DEXA Scan Looks Wrong: What The Research Describes

the dexa moment

You did the body composition scan because you're optimizing. Maybe a longevity practice ordered it. Maybe you went to a sports medicine clinic that had the equipment. Maybe Function Health or one of the longevity panels sold you the package. You expected the numbers to be good. You're not overweight. You exercise. You eat reasonably.

The DEXA report came back with most of the numbers in range. The one number that wasn't: visceral adipose tissue. The fat that lives around your organs, different from the subcutaneous fat you can pinch, different from the obvious fat someone heavier than you would carry. Your VAT number is in the consider intervention range or worse. You look lean. You're not lean where it matters most metabolically.

This is the moment that drives a specific search pattern, and Tesamorelin is what shows up in it. The peptide has a real FDA-approved indication for visceral fat, a real mechanism, and real trial data. Worth understanding what the research actually shows, and what the broader GH-axis peptide landscape looks like.

what tesamorelin actually is

Tesamorelin is a synthetic analog of growth hormone releasing hormone (GHRH). It's a 44-amino-acid peptide that's been chemically modified (a small molecular addition called a trans-3-hexenoyl group at one end) to extend its stability in the body. The base structure is the same as natural GHRH; the modification lets it stay biologically active longer than the native peptide would.^[1]

Mechanistically, Tesamorelin binds the GHRH receptor on the pituitary and triggers growth hormone release. Same general pathway as Sermorelin, but with a different pharmacokinetic profile. The clinical effect: a sustained, somewhat amplified GH pulse that downstream produces elevated IGF-1 and the various tissue effects associated with growth hormone exposure.

It was FDA-approved in 2010 under the brand name Egrifta, specifically for a narrow indication: treatment of excess visceral abdominal fat in HIV-infected patients with lipodystrophy. The lipodystrophy story is its own thing. Antiretroviral medications historically caused a specific body composition syndrome involving disproportionate visceral fat accumulation. Tesamorelin was studied and approved for that population.

The Phase 3 trials in HIV-associated lipodystrophy showed something specific and real: roughly 15-18% reduction in visceral adipose tissue over 26 weeks of treatment, measured by CT scan. That's a meaningful effect size, not a small statistical signal, but a clinically visible change in the imaging.^[2]

the off-label question

If Tesamorelin reliably reduces visceral fat in HIV-associated lipodystrophy, does it work for non-HIV patients with elevated visceral fat, the kind of patient who shows up with a DEXA report and a what now question?

The answer the research community has been working toward: probably yes, but the trial data outside of HIV is thinner.

The mechanism reasoning supports broader applicability. Visceral adipose tissue responds to GH-axis signaling regardless of why it accumulated in the first place. The lipolytic effect of elevated GH on visceral fat is well-characterized. It's not unique to HIV-related lipodystrophy. The lipodystrophy patients were just the population in whom the FDA trial was conducted.

Several studies have looked at Tesamorelin outside of HIV, most notably in non-alcoholic fatty liver disease (NAFLD) populations, where the mechanism of interest overlaps (visceral and hepatic fat). A 2019 trial published in The Lancet HIV showed Tesamorelin reduced liver fat and visceral fat in obese, non-HIV patients with NAFLD over 12 months, with effect sizes in roughly the same range as the lipodystrophy trials.^[1]

The extrapolation to a healthy biohacker with elevated VAT on DEXA but no NAFLD diagnosis and no HIV is mechanistically reasonable but not directly trial-validated. The peptide does what it does (produce a GH pulse with downstream lipolytic effects on visceral fat) regardless of the original cause of the accumulation. The treatment effect is on the fat, not on the underlying pathology that produced it.

where it fits in the broader gh-axis picture

Tesamorelin is one peptide in a class. The mechanism (producing an amplified GH pulse with downstream IGF-1 elevation and tissue effects) is shared across the GH-secretagogue category. The other peptides worth knowing about for context:

Sermorelin. A 29-amino-acid fragment of GHRH, the shortest and most-established GHRH analog. Pulsatile mechanism (short half-life). Decades of clinical use through 503A compounding pharmacies. The original what does the GH-axis pathway feel like peptide for most clinicians using this class, and the one most commonly prescribed for general body composition and sleep-architecture indications. Most longevity-focused telehealth platforms (Pepvio included) work with Sermorelin as their primary GH-axis option.

CJC-1295. Another GHRH analog. Currently on the FDA Category 2 list, so not legally compoundable in the US right now. Discussed in CJC-1295/Ipamorelin and the 3 AM wake-up pattern.

Ipamorelin. A ghrelin-receptor agonist (different mechanism than GHRH analogs, complementary effect when combined). Also on Category 2.

For the specific I have elevated VAT and want to use a GH-axis peptide to address it question, the practical landscape today comes down to two peptides that are legally compoundable: Sermorelin and Tesamorelin. They share the same fundamental mechanism (GHRH-receptor activation) and produce the same general class of downstream effect (GH pulse, IGF-1 elevation, lipolytic effects on visceral fat). The differences between them are in degree, not category.

sermorelin vs tesamorelin for this specific use case

If you've read about both peptides and you're wondering which one matters more for the visceral fat indication, here's the honest comparison.

Pharmacokinetics. Tesamorelin has a longer half-life and produces a more sustained GH response. Sermorelin has a shorter half-life and a more strictly pulsatile response. The argument for the longer-duration peptide is more total GH exposure, more downstream effect. The argument for the more pulsatile peptide is preservation of the natural release pattern and a more forgiving side effect profile.

Effect magnitude in trials. Tesamorelin has the direct visceral-fat trial data (lipodystrophy and NAFLD trials, with measurable reductions on imaging). Sermorelin's body-composition trial data is older and less specifically targeted to visceral fat as the primary endpoint, but the GH-pulse mechanism is the same and the downstream effects on body composition are documented across decades of clinical use.

Side effect profile. Both peptides share the GH-axis side effect potential: occasional joint pain, fluid retention, mild glucose intolerance with sustained use. Tesamorelin's longer-duration effect can amplify these. Sermorelin's pulsatile profile is generally considered more forgiving.

Clinical experience and accessibility. Sermorelin has substantially more accumulated clinical experience because it's been compoundable through 503A pharmacies since the 1990s. It's the workhorse of the longevity-clinic GH-axis category and the peptide most telehealth platforms (Pepvio included) offer for this indication. Tesamorelin's clinical use is largely concentrated in HIV-specialty practice plus specific longevity providers who work with networks that prescribe it off-label.

The honest summary for someone in the DEXA-VAT situation: Sermorelin is the GH-axis peptide that fits the legitimately accessible through standard telehealth channels description. It produces the same class of effect as Tesamorelin through the same receptor pathway, at a lower effect magnitude but with a more forgiving profile and substantially more clinical track record. For the specific elevated VAT in an otherwise healthy adult indication, Sermorelin is the practical conversation worth having.

For the head-to-head detail on these two peptides, see Sermorelin vs Tesamorelin. For the timeline of what Sermorelin does for body composition specifically, see Sermorelin and body composition: what the 12-week timeline actually looks like.

what to expect with a gh-axis peptide for this

If you do end up on a GH-axis peptide protocol for elevated VAT (most likely Sermorelin, given accessibility), the realistic timeline:

Months 1-2. Body composition changes are not happening yet at a visible level. The metabolic effects (elevated GH and IGF-1) start within days, but the lipolytic effects on visceral fat are slow and take time to accumulate.

Months 3-6. The window where the body composition shifts in the published research typically start to show up. If you're tracking with DEXA scans (and you should be, if VAT reduction is the specific goal), a follow-up scan at month 6 is the meaningful first checkpoint.

Months 6-12. Continued accumulation of effect, generally at a slower pace. Most of the body-composition change happens in the months 3-9 window.

Side effects to expect. Injection-site reactions are most common. Some patients experience mild joint pain or fluid retention, both classic GH-axis side effects, generally manageable, sometimes dose-limiting. Glucose intolerance can develop with elevated GH; baseline metabolic labs and periodic monitoring is standard. Most clinicians check fasting glucose and hemoglobin A1c at baseline, 3 months, and 6 months.

What it isn't. GH-axis peptides aren't weight-loss medications. If you weigh 200 pounds and want to weigh 170, this isn't your tool. They also aren't muscle-building or anti-aging cure-alls. The effect is on body composition (specifically the GH-axis-mediated shifts in fat partitioning and lean mass), not on the scale.

the broader question about visceral fat

Worth ending on the bigger picture, because the pharmacological intervention is one piece of a larger puzzle.

Elevated visceral adipose tissue is a metabolic-health signal that's worth taking seriously. It's associated with insulin resistance, cardiovascular disease risk, NAFLD, certain cancers, and various inflammatory states. The DEXA scan that flagged it isn't a cosmetic concern. It's pointing at underlying metabolic biology that's worth addressing.

The non-pharmacological interventions for visceral fat are real and substantial.

Resistance training, specifically. Has stronger effect on visceral fat than cardio alone in some research. The mechanism appears to involve insulin sensitization in muscle, which downstream affects how fat partitions.

Insulin sensitivity work. Continuous glucose monitor use to understand your specific patterns. Carb timing around exercise. Strategic carb reduction in some contexts. Working with a clinician who actually understands metabolic flexibility rather than defaulting to eat less, move more.

Sleep architecture. Poor sleep (particularly insufficient slow-wave sleep) is associated with visceral fat accumulation through cortisol and GH-axis effects. Addressing sleep is upstream of a lot of what visceral fat is reflecting.

Alcohol audit. Heavy alcohol consumption preferentially accumulates as visceral fat in some demographics. The midlife visceral fat pattern in moderately-drinking adults is often more about alcohol than about anything else.

The peptide conversation is real, but it's not a substitute for the upstream work. A GH-axis peptide might reduce your VAT number by some meaningful margin over 6-12 months. The combination of resistance training, sleep optimization, and reasonable alcohol/dietary discipline can produce similar or larger effects without any pharmacology. The peptide is most powerful in combination with the upstream work, not as a replacement for it.

For the related conversation on perimenopausal visceral fat specifically (a substantial subset of readers in this category), see perimenopause belly fat: what HRT alone doesn't fix.

the summary

The DEXA-driven self-referral pathway to peptide therapy is one of the most rational reasons to be in a conversation about GH-axis support. The mechanism and the indication actually align: elevated visceral fat in someone with reasonable body composition otherwise is exactly the kind of metabolic picture that the GH-axis-pulse mechanism is positioned to address.

Tesamorelin has the more direct trial evidence for the specific VAT-reduction indication. Sermorelin has the longer clinical experience, the broader accessibility, the more forgiving profile, and substantially the same underlying mechanism. For most readers in this situation, Sermorelin is the conversation worth having, through a real intake with a clinician who can evaluate your specific situation, set the right dose, and track real endpoints (DEXA scans at 6-month intervals, metabolic labs, IGF-1 response).

The right path forward, in order of operations:

1. Verify the DEXA finding. One scan can be off; repeat or pair with another modality (CT, MRI) if the number is borderline. Talk to your doctor about whether the finding is clinically significant for your specific picture. 2. Address the upstream drivers if they exist. Sleep, alcohol, exercise pattern, dietary patterns. Larger effect sizes than peptides, accessible immediately. 3. Consider the GH-axis peptide conversation if the upstream work isn't fully addressing it. Sermorelin through a structured intake is the practical path. The mechanism is the same class as Tesamorelin; the effect magnitude is somewhat lower but the access and clinical track record are stronger. 4. Track real endpoints. DEXA scans at 6-month intervals. Metabolic labs. Not just do I feel better (which can be misleading on GH-axis peptides because of the subjective effects on energy and recovery).

For the broader regulatory framework around peptide therapy generally, see the current state of peptide legality.